Some medicines never reach patients because the right partner was never found.

We believe there are successful medications that never make it to market, not because they failed, but because the right partner was never found.

We see it across the board: in academia, in biotech, and inside large pharma portfolios. Programs with real data and real signal reach a point where the next step depends on timing, capital, or geography rather than the science itself. It is a common situation, and one the industry has never had a good answer for.

Unobio was built to be that missing counterparty. We license promising assets and build them into focused US companies, pairing each program with dedicated operators, capital, and a development plan aimed squarely at the next inflection point.

Our work takes two forms, and they usually run together. We in-license clinical- and late-preclinical-stage assets from universities, biotechs, and pharma partners looking for the right home for a program. And where an asset warrants its own dedicated vehicle, we form a US company around it.

A US NewCo gives a program a set of advantages that are hard to assemble otherwise: a management team whose only mandate is that asset, a clean cap table, proximity to the FDA, and access to the deepest pool of life-sciences capital in the world. Originators stay in through equity, milestones, royalties, or some combination, so the people who created the science share in what it becomes.

Every situation is different, and we don’t pretend otherwise. Structures get built around the asset and the people behind it, not the reverse. What stays constant is the intent: get good science out of the drawer and back on a path toward patients.